Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of "Buy" from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been given an average recommendation of "Buy" by the seven brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $51.60.

TARS has been the subject of a number of analyst reports. William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. Oppenheimer reissued an "outperform" rating and set a $63.00 price objective (up from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS traded down $1.09 during mid-day trading on Monday, hitting $46.21. The company's stock had a trading volume of 705,930 shares, compared to its average volume of 718,016. The firm has a market capitalization of $1.76 billion, a PE ratio of -10.59 and a beta of 1.00. Tarsus Pharmaceuticals has a one year low of $15.47 and a one year high of $48.60. The stock's 50-day moving average is $33.97 and its two-hundred day moving average is $31.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 6.99 and a current ratio of 7.03.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.10. The firm had revenue of $40.81 million during the quarter, compared to analysts' expectations of $31.30 million. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. During the same period last year, the business earned ($1.17) earnings per share. As a group, sell-side analysts anticipate that Tarsus Pharmaceuticals will post -3.71 EPS for the current year.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Emerald Advisers LLC acquired a new stake in Tarsus Pharmaceuticals in the third quarter worth about $4,812,000. Harbor Capital Advisors Inc. increased its position in Tarsus Pharmaceuticals by 57.5% in the third quarter. Harbor Capital Advisors Inc. now owns 18,105 shares of the company's stock worth $595,000 after purchasing an additional 6,612 shares during the period. Emerald Mutual Fund Advisers Trust acquired a new stake in Tarsus Pharmaceuticals in the third quarter worth about $3,608,000. China Universal Asset Management Co. Ltd. increased its position in Tarsus Pharmaceuticals by 64.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company's stock worth $241,000 after purchasing an additional 2,879 shares during the period. Finally, E. Ohman J or Asset Management AB increased its position in Tarsus Pharmaceuticals by 20.5% in the third quarter. E. Ohman J or Asset Management AB now owns 46,981 shares of the company's stock worth $1,545,000 after purchasing an additional 8,000 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.